Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Georgios Papadakis
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05586802CT.gov Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Klinefelter Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Chorionic Gonadotropin (this asset) | Georgios Papadakis | P3 | B · 60 |
| Fenofibrate | University of Colorado, Denver | P4 | B |
| Anastrozole | Georgios Papadakis | P3 | B |
| Testosterone Undecylate | Georgios Papadakis | P3 | B |
| Semaglutide | Georgios Papadakis | P3 | B |
Other indications for Human Chorionic Gonadotropin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Infertility Disorder | — | P4 | BBB · 78 |
| Anovulation | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Chorionic Gonadotropin in Klinefelter Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-chorionic-gonadotropin-klinefelter-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →